Azithromycin (AZM)

population PBPK/PD

Azithromycin has relatively broad but shallow antibacterial activity. It appears to be effective in the treatment of chronic obstructive pulmonary disease through its suppression of inflammatory processes and potentially useful in asthma and sinusitis via this mechanism. Azithromycin is believed to produce its effects through suppressing certain immune responses that may contribute to inflammation of the airways. Azithromycin has also shown to inhibit Zika virus and SARS-CoV-2 (the pathogen responsible for COVID-19) growth in vitro.

These simulations are presented to inform researchers and provide a tool for discussing target concentrations in the relevant tissue (lung) over time. Not presented is the variability of target concentration, but between-subject variability in pharmacokinetics was simulated. The simulations have not accounted for differences in protein binding between the in vitro cell culture systems and protein binding in either plasma or lung.